Skip to content

Educational

News from the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting

Brought to you by Anne Mette Buhl, PhD, OCRA’s senior director of treatment access and scientific education

The 2026 annual meeting of the Society of Gynecologic Oncology took place in San Juan, Puerto Rico from April 10-13, 2026. The meeting centered on the theme “Advancing Science. Empowering Teams. Embracing Change.” Here are some of the main findings that were presented:

ROSELLA trial: The combination of nab-paclitaxel (Abraxane) and relacorilant (Lifyorli) is now an FDA approved treatment option for platinum resistant ovarian cancer
The final overall survival data from the ROSELLA trial confirmed that the combination of weekly nab-paclitaxel (Abraxane) with relacorilant (Lifyorli), a drug that blocks the effects of the stress hormone cortisol in cancer cells, extended survival compared to nab-paclitaxel (Abraxane) alone for patients with platinum-resistant ovarian cancer. Importantly, this treatment can work for a broad group of patients because it does not require a specific tumor biomarker. The combination was recently approved by the FDA and represents a new treatment option for platinum resistant ovarian cancer patients.

NRG-GY019 trial: Letrozole (Femara) combined with chemotherapy is the new standard initial therapy for advanced low-grade serous ovarian cancer
For patients with newly diagnosed stage II–IV low-grade serous ovarian cancer (LGSOC) who have had surgery, results from the NRG-GY019 trial showed that starting with standard chemotherapy followed by maintenance hormone therapy with letrozole (femara) keeps the cancer under control longer than using letrozole (femara) alone, making this combined approach the new standard of care. While letrozole (femara) alone caused fewer side effects, it did not perform as well as the combined approach in delaying cancer progression.

Antibody Drug Conjugates (ADCs) continue to show promising results in gynecologic cancers
Antibody drug conjugates, a treatment that delivers chemotherapy directly to cancer cells, represent a rapidly growing group of new treatment options for gynecologic cancers. At the SGO meeting, multiple trials with ADCs reported encouraging early results, including mocertatug rezetecan (Mo-Rez) in ovarian and endometrial cancer, sofetabart mipitecan (Sofe-M) in ovarian cancer, trastuzumab pamirtecan (T-Pam) in endometrial cancer, and sacituzumab tirumotecan (Sac-TMT) combined with pembrolizumab (Keytruda) in cervical cancer. While these findings are still early, large phase 3 clinical trials are already underway or being planned to better understand how these treatments may be used.


RUBY trial: Long-term results show continued benefit of immunotherapy in advanced endometrial cancer
The RUBY trial is a large global study that found adding the immune checkpoint inhibitor dostarlimab (Jemperli) to standard chemotherapy improves outcomes for patients with advanced or recurrent endometrial cancer. New results presented at SGO, after four years of follow-up, confirm that this combination helps patients live longer and keeps the cancer under control for longer. The greatest benefit is seen in patients whose tumors are deficient in mismatch repair (dMMR), where few patients have seen their cancer worsen even after several years. Overall, these findings support using immunotherapy plus chemotherapy as a standard first treatment for advanced endometrial cancer and offer hope for more durable, long-lasting responses.

The SISTER study emphasized the importance and impact of peer support for Black women with endometrial cancer
The SISTER study is a first-of-its-kind national clinical trial designed to improve outcomes for Black women with endometrial cancer. Results presented at SGO highlight how peer support can make a meaningful difference. Researchers found that having one-on-one support from another patient significantly increased the chances of completing treatment. This is important because Black women are less likely to complete treatment and are about twice as likely to die from endometrial cancer compared to White women, even though their cancers respond similarly to therapy. The study shows that providing strong social support can help improve treatment outcomes and potentially save lives.

For more updates, sign up for OCRA’s webinar: Gynecologic Cancer Updates from SGO, ASCO and ESMO Gyn, Spring 2026 on June 24th, 2026.

What You Can Do